Synthesis, anticoagulant and PIVKA-II induced by new 4-hydroxycoumarin derivatives

A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS

J.T. LITCHFIELD, Frank Wilcoxon · Journal of Pharmacology and Experimental Therapeutics · 1949 · 7.3K citations

Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin

Renpei Nagashima, Robert A. O’Reilly, Gerhard Levy · Clinical Pharmacology & Therapeutics · 1969 · 231 citations

Pharmacotherapy, Pharmacologic Effects, Physiologically-based Pharmacokinetic Modeling +24

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Mimi L. Quan, Patrick Y. S. Lam, Qi Han et al. · Journal of Medicinal Chemistry · 2004 · 188 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +17

Discovery of 1-[3-(Aminomethyl)phenyl]-<i>N</i>-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1<i>H</i>-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Shuaige Wang et al. · Journal of Medicinal Chemistry · 2001 · 172 citations · Full text

Vitamin K epoxide reductase: homology, active site and catalytic mechanism

Leo Goodstadt · Trends in Biochemical Sciences · 2004 · 151 citations

Biochemistry, Natural Sciences, Active Site +6